A Practitioner’s Guide to Prescribing Phenytoin for Adults with Intellectual Disabilities
Reference132 articles.
1. Adín, J., Gómez, M. C., Blanco, Y., Herranz, J. L., & Armijo, J. A. (2004). Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications. Therapeutic Drug Monitoring, 26, 251–257. 2. Ahn, J. E., Cloyd, J. C., Brundage, R. C., Marino, S. E., Conway, J. M., Ramsay, R. E., et al. (2008). Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy. Neurology, 71, 38–43. 3. Aldenkamp, A. P., De Krom, M., & Reijs, R. (2003). Newer antiepileptic drugs and cognitive issues. Epilepsia, 44(Suppl 4), 21–29. 4. Anderson, G. D. (1998). A mechanistic approach to antiepileptic drug interactions. The Annals of Pharmacotherapy, 32, 554–563. 5. Anderson, G. D., Gidal, B. E., Messenheimer, J. A., & Gilliam, F. G. (2002). Time course of lamotrigine de-induction: impact of step-wise withdrawal of carbamazepine or phenytoin. Epilepsy Research, 49, 211–217.
|
|